Dr Reddy's Laboratories is preparing to launch next month the injectable drug remdesivir for hospitalised COVID-19 patients, as well as the oral drug favipiravir, which is given to those with mild-to-moderate coronavirus infection, reported Business Standard.
CEO Erez Israeli indicated that these products are being launched with a longer horizon in mind, not just targeted for the pandemic, but he also believes COVID-19 is here to stay for at least another year, so coronavirus-targeted products are likely continue to do well.
"Unless a vaccine surprises us, the pandemic is here to stay at least for a year or so. Our data on favipiravir is showing it is a good product," Israeli said.
Dr Reddy's is going to launch the innovator brand Avigan of favipiravir as part of a tie up it has with Fujifilm Toyama Chemical Co and Global Response Aid.
While Israeli did not wish to comment on the pricing of Avigan in India, he said that since they would have access to clinical data from the innovator, they have the opportunity to market it to other countries.
According to the news source, Dr Reddy's has the rights to sell the drug overseas other than in Japan, China and Russia.
To read more NewsPoints articles, click here.